Actively Recruiting
Use of CA125 and Complementary Biomarkers for the Early Detection of Ovarian Cancer in Low Risk Women
Led by M.D. Anderson Cancer Center · Updated on 2026-05-06
8000
Participants Needed
12
Research Sites
1430 weeks
Total Duration
On this page
Sponsors
M
M.D. Anderson Cancer Center
Lead Sponsor
N
National Cancer Institute (NCI)
Collaborating Sponsor
AI-Summary
What this Trial Is About
The goal of this clinical research study is to find out if combining a standard blood test (CA-125) that checks for ovarian cancer with other blood tests that check for related tumor markers may be helpful in the early detection of ovarian cancer in women who are at low risk. Tumor markers are substances in the blood that may be related to ovarian cancer.
CONDITIONS
Official Title
Use of CA125 and Complementary Biomarkers for the Early Detection of Ovarian Cancer in Low Risk Women
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Female aged 50 to less than 75 years
- Postmenopausal for at least 12 months (no menstrual periods)
- Have at least one ovary
- Cancer-free and no chemotherapy or radiation therapy in the past 12 months
- Willing to return annually or earlier for CA-125 blood tests
- Willing to have a transvaginal ultrasound if recommended
- Provide the name of a gynecologist or healthcare professional for follow-up care if needed
You will not qualify if you...
- Female younger than 50 or 75 years and older at enrollment
- Psychiatric, psychological, or other conditions preventing informed consent
- Both ovaries removed
- Active non-ovarian cancer
- History of non-ovarian cancer with persistent or recent disease or treatment within 12 months (except basal cell carcinoma treated less than 12 months ago)
- High risk for ovarian cancer due to familial predisposition or known genetic mutations (BRCA1, BRCA2, Ashkenazi Jewish descent with relevant family history, male relative with breast cancer)
- Known hereditary nonpolyposis colorectal cancer (HNPCC)/Lynch Syndrome or related genetic mutations
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 12 locations
1
Sylvester Comprehensive Cancer Center, Univ of Miami Miller School of Medicine
Miami, Florida, United States, 33136
Actively Recruiting
2
John Stoddard Cancer Center
Des Moines, Iowa, United States, 50309
Actively Recruiting
3
University of Minnesota
Minneapolis, Minnesota, United States, 55454
Actively Recruiting
4
Carol G. Simon Cancer Center / Atlantic Health
Morristown, New Jersey, United States, 07962
Actively Recruiting
5
University of Rochester Medical Center
Rochester, New York, United States, 14642
Actively Recruiting
6
University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma, United States, 73104
Actively Recruiting
7
Women's and Infant's Hospital
Providence, Rhode Island, United States, 02905
Actively Recruiting
8
The University of Texas at Austin
Austin, Texas, United States, 78712
Active, Not Recruiting
9
University of Texas (UT) Southwestern Medical Center
Dallas, Texas, United States, 75390
Active, Not Recruiting
10
University of Texas MD Anderson Cancer Center
Houston, Texas, United States, 77030
Actively Recruiting
11
Women's Hospital of Texas, Obstetrics and Gynecology Associates (OGA)
Houston, Texas, United States, 77054
Actively Recruiting
12
UT Health Science Center San Antonio
San Antonio, Texas, United States, 78229
Actively Recruiting
Research Team
G
Gwen H. Corrigan
CONTACT
S
Study Coordinator MD Anderson
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
SCREENING
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here